- Home
- ALX vs RLAY Comparison
ALX vs RLAY Comparison
Compare ALX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | RLAY |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ALX | RLAY |
|---|---|---|
| Price | $217.16 | $8.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 44.8K | ★ 2.1M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $215,838,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $184.76 | $1.78 |
| 52 Week High | $260.84 | $8.70 |
Technical Indicators
Market Signals| Indicator | ALX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 68.59 |
| Support Level | $212.03 | $7.42 |
| Resistance Level | $219.61 | $8.70 |
| Average True Range (ATR) | 4.49 | 0.45 |
| MACD | 1.21 | 0.03 |
| Stochastic Oscillator | 74.97 | 88.10 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).